Mark Hyman Rapaport, MD is the Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine and Chief of Psychiatric Services at Emory Healthcare in Atlanta, Georgia. Before coming to Atlanta, Dr. Rapaport was the Chairman of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center and a Professor of Psychiatry at both Cedar-Sinai and the David Geffen School of Medicine at UCLA. He was the first holder of the Polier Chair while at Cedars-Sinai. Dr. Rapaport also previously served as Director of the Mental Health Outpatient Clinical Research Center in the Department of Psychiatry at University of California, San Diego (UCSD) and has served as the first Chair of the National Institute on Drug Abuse (NIDA) Clinical Trials Network's Data Safety Monitoring Board and Chair of its Special Review Committee. He has served on NIH and NIMH Review Committees. Dr. Rapaport has received peer-reviewed grant funding from the National Institute of Mental Health (NIMH), National Center for Complimentary and Alternative Medicine, The Stanley Medical Research Institute, the Veterans Affairs Research Board and the National Alliance for Research on Schizophrenia and Depression (NARSAD) Foundation. Dr. Rapaport has trained and mentored students, physicians and researchers in the fields of psychopharmacology, outcomes research, and psychoneuroimmunology. A board-certified psychiatrist, Dr. Rapaport has written over 180 articles for such peer-reviewed publications as American Journal of Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry and Neuropsychopharmacology. He currently serves as Co-Editor and Chief of FOCUS: The Journal of Lifelong Learning in Psychiatry, published by American Psychiatric Publishing, Inc. and the American Psychiatric Association. Dr. Rapaport is a member of the American College of Psychiatrists, American Society of Clinical Psychopharmacology, Anxiety Disorders Association of America, the Psychiatric Research Society and the Collegium International Neuropsychopharmacology (CINP) and the American College of Neuropsychopharmacology (ACNP). He is a distinguished fellow of the American Psychiatric Association and the CINP.

Mark Hyman Rapaport's research interests include: Psychopharmacology, and he has investigated the biologic genesis of anxiety disorders, bipolar disorder, depression and immunity abnormalities in psychotic and mood disorders.

Not new issue